One of the targeted recipients, Tiba Biotech, had a $750,000 contract with BARDA that was slated to end October 30. The company was developing an RNAi-based therapeutic for H1N1 influenza, also known… [+3908 chars]Read More
RFK Jr Is Supporting mRNA ResearchJust Not for Vaccines WIRED
